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Objectives. Third-generation cardioverter-defibrillators appear
to be susceptible to unique sensing errors . This study was per-
formed to determine the incidence and types of sensing errors in
combination therapy implantable devices .
Background, One of the advantages offered by third-generation
implantable cardloverter-defibrillators is the combination of bra-
dycardia and antitachycardia pacing and cardioversion.
defibrillation capabilities in a single device . The potential for
unique sensing errors, those caused by the conflicts presented by
combining bradycardla and tachyeardia sensing and therapy
algorithms in the same device, has not been previously addressed .
Methods. To determine the incidence of important sensing
errors, 61 patients with a combination therapy device (Cadence
[Ventritex] and PCD [Medtronicl) were studied for a 25-month
period. In addition to surface electrocardiographic recordings
during implantation and routine device testing, real-time and
The potential for adverse interactions between physically
separate bradycardia pacemakers and implantable cardio-
verter-defibrillators has been documented (1-3) . The most
important of these interactions is failure to detect ventricular
fibrillation due to device sensing of pacemaker stimulus
artifacts that continue during the arrhythmia (1,4) . One of
the advantages offered by third-generation implantable de-
vices is the combination of bradycardia and antitachycardia
pacing and cardioversion-defibrillation capabilities in a sin-
gle unit. Typically, both bradycardia and tachycardia sens-
ing are performed using the same lead system and are
governed by a single-decision algorithm.
Previous observations in a limited number of patients (5)
demonstrated that unique sensing errors can occur in com-
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stored electrograms recorded from the rate-sensing leads (Ca-
dence) and real-time marker channel recordings (PCD) were
reviewed to diagnose sensing errors that resulted is symptoms,
device inefficacy or delivery of inappropriate therapy. After
recognition, specific reprogramming steps were performed In an
attempt to avoid recurrent sensing errors .
Results. A total of 13 sensing errors were diagnosed in 12
patients (19 .7%); the incidence was similar in both devices . Five
distinct categories of sensing errors were identified . After device
reprogramming, only one recurrent error occurred in 98 patient-
months of follow-up .
Conclusions. Important sensing errors occur in approximately
20% of patients with third-generation combination therapy car-
dioverter-defibrillators . Prompt diagnosis of sensing errors can
lead to specific reprogramming steps to avoid recurrent errors.
(J Am Coll Cardiol 1993 ;22:1135-40)
bination therapy devices . These sensing errors were caused
by the complexities of combining bradycardia and tachycar-
dia sensing and therapy algorithms in a single device . This is
to be distinguished from sensing errors caused by the phys-
ical limitations of device technology or by programming
mistakes.
The purpose of this study was to determine the incidence
of important sensing errors in a more comprehensive series
of patients with a combination therapy device. In addition,
the study was designed to determine whether device repro-
gramming after error recognition was effective in preventing
recurrent episodes .
Methods
Study patients. Sixty-one patients who received a com-
bination therapy device (August 1989 to September 1991)
were studied for 797 patient-months . All patients had struc-
tural heart disease and refractory ventricular arrhythmias .
The third-generation devic6s included in the study were the
Cadence (Ventritex) in 48 patients and the PCD (Medtronic)
in 13 patients . Written, informed consent was obtained from
all patients. The study protocol for device implantation and
follow-up was approved by the Institutional Review Board
of the University of Pennsylvania .
0735-1097/93156.00
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Figure 1 . This sequence begins with electrograms identical to those
registered during reahtime recordings of sinus rhythm in this patient
(arrows)
. A 6-beat run of nonsustained ventricular tachycardia (VT)
with a different electrogram morphology and large amplitude signals
occurs . The next electrogram, which follows at a long interval, is
identical in morphology to the sinus beats at the beginning of the
sequence but has a much smaller amplitude . This beat is not sensed,
as evidenced by the delivery of a pacing stimulus (s) at the
'prgrammed vent ricular •inhibited (VVI) pacing interval
(S0 beats/min (bpmll1,200 ms) from the large amplitude electrogram .
This long-short coupling sequence resulted in the initiation of
ventricular tachycardia, which was subsequently terminated by the
device,
Device knplantation. In seven patients a nonthoracotomy
lead system (PCD), which consisted of endocardial energy-
delivering-pacing-sensing leads with or without a subcutane-
ous patch lead, was implanted . Six patients had a new
generator connected to existing energy-delivering and rate-
sensing lead systems . Most patients received two epicardial
patch energy-delivering leads and a rate-sensing--pacing lead
system consisting of an endocardial in-line bipolar lead (16
patients) or two epicardial screw-in electrodes (32 patients).
Before implantation, the following specifications were doc-
umented: 1') an R wave amplitude >5 mV during spontane-
ous rhythm (>4 mV for chronic lead systems), 2) a pacing
threshold s 1 .5 V at 0.5-ms pulse width (s2 V in chronic lead
systems), and 3) a defibrillation threshold x550 V (Cadence)
or 18 3 (PCD), Device efficacy for detection and termination
of all inducible ventricular arrhythmias was assessed infra
operatively, Detailed testing was also performed I and 6
weeks postoperatively, with induction of ventricular ar-
rhythmias using noninvasive programmed stimulation .
We ampisition and analysis. In addition to surface elec-
trocardiographic recordings during implantation and routine
device testing, the following information was reviewed for
diagnosis of sensing errors: for PCD, direct recordings from
the rate-sensing and energy-delivering lead during device
implaantation and real-time marker channel recordings during
device testing
; for cadence, direct recordings from the
rate-sensing and energy-delivering lead systems during de-
vice implantation, real-time electrograms recorded from the
rate-sensing leads during device interrogations and stored
electrograms recorded from the rate-sensing leads during
events leading to therapy delivery for spontaneous arrhyth-
I
1200 ms
mias. The utility of stored electrogram analysis in the
diagnosis of spontaneous arrhythmias has been previously
reported (6) . After recognition of a sensing error that re-
sulted in significant symptoms, device inefficacy or inappro-
priate delivery of therapy, a specific programming interven-
tion was performed, if possible, to prevent recurrent errors .
Results
Five different categories of sensing errors were observed :
t) transient sensing failure during sinus rhythm caused by an
abrupt change in the amplifier gain setting, 2) transient
sensing failure during sinus rhythm caused by spontaneous
variatiun in signal amplitude, 3) inappropriate inhibition of
bradycardia pacing due to T wave oversensing, 4) inappro-
priate antitachycardia therapy caused by T wave oversens-
ing during sinus rhythm, and 5) ineffective antitachycardia
pacing due to inaccurate detection of the tachycardia cycle
length.
Transient sensing failure during sinus rhythm caused by an
abrupt change in the amplifier gain setting (Fig. 1). The sense
amplifier adapts continuously to the characteristics of the
incoming signal by adjusting either the gain setting (Ca-
dence) or the sensing threshold (PCD) . Tb • -e adjustments
are not instantaneous but require either a fixed number of
signals of significantly different amplitude or the passage of a
fixed amount of time before going into effect . If a series of
large amplitude signals interrupts sinus rhythm (for example,
nonsustained ventricular tachycardia), the gain will be de-
creased to prevent amplifier saturation . This adjustment can
lead to a transient inability to sense the next sinus signal . In
the absence of a sensed R wave, a pacing stimulus is
delivered at the programmed escape interval after the last
large amplitude beat. The resulting long-short stimulation
sequence can result in device-mediated initiation of tachy-
cardia in susceptible patients .
Two patients had sustained ventricular tachycardia initi-
ated by inappropriate pacing stimuli delivered in association
with this sensing error. Both tachycardias were promptly
detected and terminated by device therapy . The bradycardia
pacing rate was increased in both cases in an attempt to
avoid duplicating the coupling interval sequence that re-
sulted in arrhythmia induction.
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Transient sensing failure during sinus rhythm caused by
spontaneous variation in signal amplitude (Fig. 2). As de-
scribed earlier, the sense amplifier adjusts to establish a
relatively stable gain/threshold setting for the sinus rhythm
signal. A single large amplitude signal from a ventricular or
a conducted atrial premature beat will not produce a change
in the amplifier gain setting but does cause a transient
alteration in sinus cycle length . The sinus electrogram after
a premature beat can be significantly lower in signal ampli-
tude than the preceding sinus beats (7) . This spontaneous
change in signal amplitude can cause transient failure to
sense the sinus signal, resulting in the delivery of inappro-
priate pacing stimuli, potentially causing the induction of
ventricular arrhythmias .
Three patients had episodes of device-mediated tachycar-
dia induction associated with this sensing error . The tachy-
cardias were appropriately detected and terminated with
device therapy . To prevent the coupling interval sequence
that resulted in tachycardia induction, the bradycardia pac-
ing rate was increased .
Inappropriate inhibition of bradycardia pacing due to T
wave oversensing (Fig . 3) . When the lead system is used for
pacing, sensing function is intermittently suspended (blank-
Figure 3. Real time clectrograms (Egm)
are' own with simultaneous surface elec-
trocardiographic leads and time lines (T) .
A, Ventricular pacing at the programmed
ventricular-inhibited (VVI) pacing inter-
val (70 beats/min [bpml, 850 ms) . Note the
large amplitude deflections on the electro-
gram tracing, corresponding in time to the
surface T wave . B, Recorded several sec-
onds later, there is a sudden change in the
pacing cycle length to 1,250 ms . The new
paced cycle length of 1,250 ins is appar-
ently caused h v T wave oversensing as
each pacing stimulus follows the end of
the electrogram signal by the programmed
pacing interval .
I
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Figure 2 . This sequence of stored electrograms begins in sinus
rhythm. The 4th beat arrives early and has a different morphology,
presumably representing a premature ventricular beat . Although a
single large amplitude beat is not
sufficient
to adjust the gain
amplifier, the next complex, which follows at a long interval and has
a uorphology iJeotuGal to that of the preceding sinus beats, has a
significantly smaller amplitude . This beat is not sensed, as evi-
denced by the delivery of a pacing stimulus (s) at the programmed
ventricular-inhibited (VVI) pacing interval (35 beatslmin
[bpm[11,714 ms) from the large amplitude complex . This long-short
coupling sequence resulted in the induction of ventricular tachycar-
dia (W'), which was detected and terminated by the device .
ing) . During intermittent ventricular pacing, this is not
problematic because the amplifier adjusts to the amplitude of
the spontaneous R waves . In 100% paced rhythm, the only
signal that is available for sensing is the T wave and local
afterdepolarization. The sense amplifier adjusts to detect
these low amplitude events, usually by operating at maximal
gain or minimal threshold . This amplification can result in
inappropriate sensing of the T wave as a separate event,
which inhibits delivery of the next pacing stimulus and
lengthens the effective pacing escape interval .
Inappropriate inhibition of bradycardia pacing occurred
Vr 380
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in four pacing-dependent patients, resulting in symptoms
due to sustained heart rates of s40 beatslmin or frequent
pauses ;4 s in duration . The postpacing refractory period
was increased in these patients to decrease the likelihood of
T wave oversensing .
Inappropriate antitachycardla therapy caused by T wave
oversensing during sinus rhythm (Fig. 4). Appropriate
sens-
ing depends on distinguishing R waves from T waves on the
basis of amplitude differences with or without the use of a
time-dependent change in the sensing threshold down to a
programmable "floor" value (PCD). If the amplitude of the
T wave-afenkpolarization complex is not significantly less
than the R wave amplitude, it will be interpreted as an R
JACC Vol. 22, No. 4
October 1993 : 1 135-40
Figure 4. This sequence of stored
electrograms begins with sinus
tachycardia (133 beatslmin,
450 ms), well below the rate cutoff
for detecting ventricular fibrilla-
tion (VF) (270 ins). Note the rela-
tively large amplitude deflections
between R waves, which represent
local T waves. There are two in-
creases in the amplifier gain set-
2 ting, indicated by the straight
arrows. The gain steps are appar-
ently performed to better interpret
the low amplitude portions of the
signal to prevent missing a diagno-
sis of fine ventricular fibrillation .
The T wave signal was eventually
magnified sufficiently to cause
double counting, resulting in spu-
rious detection of ventricular fi-
brillation and the delivery of a
500-V shock. NSR = normal sinus
rhythm.
wave, The resultant "double-counting" can result in spuri-
ous tachycardia detection .
Device therapy was delivered during sinus rhythm at
rates well below the cutoff for tachycardia detection because
of T wave oversensing in two patients . In one patient, the
sensing threshold was increased to prevent recurrence. No
intervention was possible in the other patient with this
problem .
Ineffective antitachycardia pacing due to inaccurate detec-
tion of the tachycardia cycle length (Fig . 5 and 6). Two
different sensing errors occurred in this category . In the first,
appropriate antitachycardia pacing was transiently inhibited
due to T wave oversensing (Fig. 5). In the second, antitachy-
Figure S. A real time surface electro-
cardiographic (ECG) lead and marker
channels from the pacing-sensing lead
during an induced episode of ventricu-
lar tachycardia. The antitachycardia
pacing protocol was VVI burst pacing,
10 stimuli at 84% of the tachycardia
cycle length . The marker channel dem-
onstrates that the T wave after the 3rd
paced beat is counted as an R wave
(tachycardia rate zone, sensed beat
[TSI) . The next tachycardia beat is
sensed (fibrillation rate zone, sensed
beat IFS]), which results in inhibition of
the 4th beat of the burst . The remainder
of the burst is delivered but is unsuccess-
ful in terminating the tachycardia . VP =
ventricular paced event ; VR = ventric-
ular sensed event within sensing refec-
tory period ; VS = ventricular sensed
event.
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Figure 6. Surface electrocardiographic leads
1, 11 and V, during an episode of induced
vr ttricular tachycardia (VT) with a stable
cycle length of 410 ms . After tachycardia
dt section, antitachycardia pacing (pro-
gr :mmed for a burst of 12 stimuli at 85% of the
(achycardia cycle length) ensues at a cycle
length of 430 ms (i .e ., longer than the tachy-
cardia cycle length) . If 5 beats are averaged
together to determine the tachycardia cycle
length, and one interval is falsely sensed as
820 ms because of signal dropout, then anti-
tachycardia pacing will proceed at 430 ms .
T = time line .
I
VT 410 ms
cardia pacing was delivered at a cycle length greater than the
tachycardia cycle length (Fig . 6) . This was apparently due to
signal dropout during the determination of the tachycardia
cycle length. In both of these patients, there were no further
sensing errors during extensive electrophysiologic testing,
and no specific programming changes were performed .
Follow-up after device reprogramming. A total of 13
sensing errors resulting in significant symptoms or inappro-
priate device therapy were seen in 12 (19 .7%) of the 61
patients. The incidence was similar in both devices : 10 of
48 patients with the Cadence and 2 of 13 patients with the
PCD experienced problems because of sensing errors . In
10 of the 13 episodes, which occurred over a period of 73
patient-months after implantation, a specific change in de-
vice programming was performed in an attempt to prevent
recurrence. Only one recurrent error occurred after repro-
gramming over a period of 98 patient-months. The single
recurrence was an episode of ventricular tachycardia caused
by an inappropriate paced beat after a nonsensed sinus
complex, which was again treated by an adjustment in the
bradycardia pacing interval .
Discussion
Major findings. In our study, unique sensing errors re-
sulting in symptoms from bradyarrhythmias or tachyarrhyth-
mias, device inefficacy or delivery of inappropriate therapy
occurred in nearly 20% of patients with combination therapy
devices. The recognition of these sensing errors was facili-
bated by the enhanced diagnostic capabilities available in
third-generation devices . Finally, in most cases, recurrent
errors were avoided by specific programming interventions .
Unique requirements of combination therapy devices .
Sensing errors caused by the inability of present devices to
distinguish ventricular from supraventricular tachyarrhyth-
mias (4,6,8-14) and those imposed by the limitations of
available lead technology (15,16) have been well docu-
mented. This is the first comprehensive study of sensing
errors caused by the special complexities of third-gent ration
combination devices . The requirements for cardioverter-
defibrillator sensing systems are much more demanding than
those developed for bradycardia pacemakers . Accurate de-
CALLANS ET AL
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tection of ventricular fibrillation requires rapid adaptation to
a > 10-fold i tinge in signal amplitude, a situation that essen-
tially invalidates the incorporation of a fixed, programmable
sensing threshold . In addition, tachycardia-sensing algo-
rithms cannot include long postsensing refractory periods,
which bradycardia pacemakers utilize to avoid T wave
oversensing . Although present tachycardia-sensing algo-
rithms are able to meet these specifications, the addition of
bradycardia pacing presents seemingly unavoidable contra-
dictions . For example, in the absence of sensed complexes,
two potentially life-threatening diagnoses with different
treatment strategies must be considered : heart block requir-
ing bradycardia pacing and ventricular fibrillation requiring
amplifier gain adjustments for proper detection.
Several of these sensing errors are also observed in
bradycardia pacing systems. Combination therapy devices
are considerably more complicated because device repro-
gramming steps, even if effective in preventing recurrent
errors, often compromise either bradycardia- or tachycardia-
sensing functions. For example, T wave oversensing can be
easily managed in bradycardia pacing systems by readjusting
the sensing threshold . Raising the sensing threshold (PCD)
to prevent T wave oversensing during sinus rhythm imposes
potential limitations on the speed and accuracy of detecting
ventricular fibrillation . Lengthening the postpacing sensing
refractory period to eliminate T wave oversensing during
paced rhythms (Cadence) reduces the amount of time avail-
able for sensing and could conceivably prevent or delay
detection of tachycardia. Obviously, device testing is essen-
tial after significant changes in programming to ensure ade-
quate tachycardia sensing function .
Conclusions. We found important sensing errors, result-
ing in symptoms, device inefficacy or delivery of inappropri-
ate therapy in nearly 20% of patients with third-generation
combination therapy devices. This represents a considerable
improvement over the results of physically separate brady-
cardia pacemakers and cardioverter-defibrillators
(1-3,5) but
demonstrates the difficulty in combining bradycardia- and
tachycardia-sensing algorithms in a single system
. Recogni-
tion of sensing errors, facilitated by the enhanced diagnostic
capabilities of third-generation devices, allows reprogram-
ming steps to avoid recurrent sensing errors .
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